Related Experiment Videos
Nicotinamide pharmacokinetics in patients
J Dragovic1, S H Kim, S L Brown
1Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI 48202, USA.
Summary
Nicotinamide, when taken orally with radiation therapy, shows promising results for cancer treatment. Doses up to 6g are well-tolerated and may enhance radiation damage in human tumors.
Area of Science:
- Oncology
- Pharmacology
- Radiotherapy
Background:
- Recurrent and metastatic cancers pose significant treatment challenges.
- Nicotinamide is being investigated as a radiosensitizer to improve cancer treatment outcomes.
- Understanding the pharmacokinetics of nicotinamide is crucial for optimizing its therapeutic use.
Purpose of the Study:
- To analyze the pharmacokinetics of oral nicotinamide in cancer patients undergoing radiation therapy.
- To determine the relationship between nicotinamide dosage, plasma concentrations, and tolerability.
- To evaluate the potential of nicotinamide as a radiosensitizer in human tumors.
Main Methods:
- Pharmacokinetic analysis of blood samples from 12 cancer patients.
- Administration of escalating oral doses of nicotinamide (3g to 10g).
- Correlation of plasma concentrations with dosage and time post-ingestion.
Main Results:
- A linear relationship was observed between nicotinamide dose and maximum plasma concentration (r=0.91).
- Doses up to 6g were well-tolerated, reaching peak plasma levels within 30 minutes.
- Higher doses (10g) showed delayed peak levels and were less tolerated, though sustained higher concentrations.
Conclusions:
- Oral administration of 6g of nicotinamide is suggested as a safe and potentially effective dose for radiosensitization in human tumors.
- Higher doses of nicotinamide may alter pharmacokinetics and radiosensitizing effects.
- Further research is warranted to fully elucidate the role of nicotinamide in cancer therapy.